Canadian plan sponsors and insurers are revisiting how they classify obesity drugs under their benefits plans, amid plan members’ rising demand for Ozempic as a weight-loss treatment. Ozempic, also known under the generic name semaglutide, is a drug used to treat type 2 diabetes. However, the medication has also been credited as a weight-loss treatment, […]
With Yukon implementing a transitioning policy on April 3 to expand the use of biosimilar medicines in its public drug plan, it’s important for benefits plan sponsors that create a similar policy for their workplace plans to be clear in their communication and education with employees. “It’s never easy to switch a medication, especially when […]
By focusing on cancer as part of a wider chronic disease management strategy, employers can support employee health while reducing benefits costs, said Chris Bonnett, founder and principal at H3 Consulting, during a webinar hosted by the Canadian Pension and Benefits Institute. While long-term disability plans pay out, on average, $3,500 per month, cancer patients […]
As the coronavirus pandemic enters its fourth year, it’s perhaps unsurprising that the health crisis has taken its toll on employee mental health. Scotiabank saw a notable rise in claims for mental-health drugs in 2022, says Ayman Alvi, the bank’s vice-president of global pension and benefits, noting the increased use of these medications aligns with […]
Changes to Ontario’s policy on the use of biosimilars in its public drug plan could result in savings for private benefits plans if they choose to follow the provincial model, says Theresa Tran, a principal in group benefits at Eckler Ltd. Starting March 31, Ontario Drug Benefit recipients who are on an originator biologic will […]
Running for more than 17 years, Benefits Canada‘s Face to Face Drug Plan Management Forum is the industry’s most popular drug benefits conference. In 2022, the event returned to a face-to-face format at the Sheraton Centre in Toronto on Dec. 6. Attendees learned about fresh drug plan design insights, including a new drug launch panel […]
Plan sponsors face challenges balancing benefits plan sustainability while also ensuring their plan members have access to the care they need, said Marie-Hélène Dugal, manager of pharmacy benefit strategy at Medavie Blue Cross, during a session at Benefits Canada’s 2022 Face to Face Drug Plan Management Forum in Toronto in December. Referring to Medavie’s claims data, […]
With the cost of drug claims continuing to rise in 2021, benefits plan sponsors can enable certain drug programs to curb costs, keeping their plans sustainable and offering the benefits that members highly value, said Lavina Viegas, director of pharmacy operations at Telus Health, during a session at Benefits Canada’s 2022 Face to Face Drug […]
About a million Canadians are impacted by rare diseases, which disproportionately affect younger patients — 70 per cent start in childhood and, sadly, half of these children won’t reach adulthood, said Suzanne Lepage, a private health plan strategist, during a session supported by Alexion Pharmaceuticals at Benefits Canada‘s 2022 Face to Face Drug Plan Management Forum […]
An article on the potential impacts of a pension super-priority bill was the most-read story on BenefitsCanada.com over the last week. Here are the five most popular news stories of the week: 1. Pension super-priority bill passes in House of Commons 2. Ontario municipality establishing six-week indoor mask requirement for city employees 3. CIBC supporting employee health with wellness […]
aHR0cHM6Ly93d3cuYmVuZWZpdHNjYW5hZGEuY29tL3RhZy9oaWdoLWNvc3QtZHJ1Z3MvcGFnZS8zLw(U2NyZWVuSGVpZ2h0)NzIw(U2NyZWVuV2lkdGg)MTI4MA(T0ZTWVNfUmVmZXJyZXI)(dmlzaXRvcktleQ)TzdvMks5d1o(dmlzaXRLZXk)RjJMUHRtZUo){kind=small}